[Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate].
OBJECTIVE
To compare changes in biochemical markers of bone turnover in postmenopausal women who received sequential discontinuous hormone replacement therapy (HRT) with either transdermal 17 beta-estradiol gel (group 1) or oral equine sulfoconjugated estrogen (group 2), plus nomegestrol acetate.


METHODS
Prospective, open, randomized, controlled trial, conducted on 3 parallel groups of 106 postmenopausal women. All treated groups received estrogen therapy for 25 consecutive days every month. The estrogen used was either 1.5 mg/day of transdermal 17 beta-estradiol gel (group 1) [N = 42, average age (AA) = 51.6 years, average duration of menopause (ADM = 21.5 months)], or 0.625 mg/day of oral equine sulfoconjugated estrogen (group 2) [N = 39, AA = 51.3 years, ADM = 16.8 months]. In all cases nomegestrol acetate 5 mg/day was added for 12 consecutive days every month. The control group comprised 25 patients, [AA = 53.4 years, ADM = 33.7 months]. Two bone resorption markers: urinary cross-linked N-telopeptide and C-telopeptide of type I collagen (U-NTX/Cr, U-CTX/Cr), and a bone formation marker: serum bone specific alkaline phosphatase activity were measured before and 6 months after treatment start.


RESULTS
Significant decreases from baseline values were observed for the 3 biochemical markers in both treated groups compared with control (P < 0.001). There were no significant differences in changes between the 2 treated groups for the 3 biochemical markers. The mean percentage change in the 3 biochemical markers was: from -9.3 to -45.5% in group 1, from -20.5 to -39% in group 2, and from -3.3 to 2% in control group. In group 1, the mean percentage decreases in U-CTX reached optimal threshold of bone turnover change (-45%) which is considered by the International Osteoporosis Foundation as clinically relevant because it predicts an increase in BMD greater than 3% when treatment is maintained over a long term.


CONCLUSIONS
Both treated groups induced a significant comparable decrease of bone turnover markers after 6 months of intervention, compared with control. The group treated with cyclic administration of transdermal 17 beta-estradiol (1.5 mg/day) and nomegestrol acetate (5 mg/day) showed a bone resorption markers decrease corresponding to the threshold of clinical relevance described in the international literature and predictive of positive BMD response in long term.
Collette
J
J
Unité d'exploration du métabolisme osseux, CHU Brull, 45, quai Godefroid-Kurth, 4020 Liège, Belgique.
Viethel
P
P
Dethor
M
M
Chevallier
T
T
Micheletti
M C
MC
Foidart
J M
JM
Reginster
J Y
JY
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000378:metabolism; D015415:Biomarkers / Q000652:urine*; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism*; D004958:Estradiol / Q000008:administration & dosage; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D008535:Megestrol / Q000008:administration & dosage; D008875:Middle Aged; D009649:Norpregnadienes / Q000008:administration & dosage; D017698:Postmenopause; D011237:Predictive Value of Tests
D015415:Biomarkers; D004967:Estrogens; D009649:Norpregnadienes; D004958:Estradiol; C038501:nomegestrol acetate; D008535:Megestrol; D000469:Alkaline Phosphatase